Myeloma: Daratumumab Plus Lenalidomide Improves MRD …
WEB12 hours ago · September 30, 2024. 0. RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving ...
Daratumumab Plus VRd Improves MRD Negativity in Newly Diagnosed ...
WEB2 days ago · In July 2024, the FDA approved subcutaneous daratumumab plus VRd for induction and consolidation in patients with newly diagnosed multiple myeloma who are candidates for autologous stem cell ...
Sarclisa Approved for Transplant-Ineligible Newly Diagnosed Multiple ...
WEB6 days ago · Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant. News ...
DARZALEX FASPRO®-based quadruplet regimen significantly …
WEB3 days ago · CEPHEUS (NCT03652064) is an ongoing, multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of D-VRd vs VRd in patients with newly diagnosed multiple myeloma for whom ...
Multiple Myeloma: Improved Prognosis With the Latest Treatments
WEBAug 16, 2023 · What is multiple myeloma, and how is it diagnosed? Is multiple myeloma curable? What is a typical multiple myeloma prognosis? What are the newest multiple myeloma drug treatments? Why are bispecific antibodies such promising treatments for multiple myeloma? What is your vision for improving treatment for multiple myeloma over the next decade at ...
Daratumumab Plus Standard Therapy for Multiple Myeloma
WEBJan 19, 2024 · A large randomized clinical trial for people newly diagnosed with multiple myeloma has found that adding the drug daratumumab (Darzalex) to a standard treatment regimen was more effective than that standard regimen on its own.
The State of Myeloma in 2024
WEBApr 18, 2024 · As reported in the Winter 2024 edition of Myeloma Today, based on data from the ISKIA phase III clinical trial and PERSEUS clinical trials, using quadruplet (4-drug) combinations will soon become the new standard of care in the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell ...
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple …
WEBJun 3, 2024 · Isatuximab-VRd was more effective than VRd as initial therapy in patients 18 to 80 years of age with newly diagnosed multiple myeloma who were ineligible to undergo transplantation.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple …
WEBDec 12, 2023 · In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd...
FDA’s Recent Approval of 2 CAR T-Cell Therapies a ‘Big Step …
WEBRye Brook, N.Y., April 16, 2024 – The U.S. Food and Drug Administration (FDA) recently approved the CAR T-cell therapies ciltacabtagene autoleucel (cilta-cel; Carvykti™) and idecabtagene vicleucel (ide-cel; Abecma®) for earlier …